Antengene Corporation Limited announced that South Korea'sNational Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). XPOVIO® will be officially included into the national reimbursed drugs list of South Korea on July 1, 2024. MM, the second most common hematologic malignancy, is caused by the dysregulated proliferation of plasma cells.

Patients with MM face a range of challenges including a high relapse rate, short survival, and limited treatment options. According to market data, the global MM market has exceeded $17 billion in 2023 and is expected to reach USD 26 billion by 2028, with a compound annual growth rate (CAGR) of 8.7%. To date, XPOVIO® has already been included for health insurance coverage in mainland of China, Australia and Singapore in the APAC markets.

With the latest approval from the NHIS in South Korea, XPOVIO® is poised to be a novel treatment option and will bring clinically meaningful survival benefits to more patients in need. Antengene has already submitted NDAs for XPOVIO® in Thailand, Malaysia and Indonesia for the treatment of patients with R/R MM and R/R diffuse large B-cell lymphoma (R/R DLBCL).